1y return+99.5%S&P 500 +20.9%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2023: $216 against $157 in the S&P 500.2
Exome Asset Management LLCS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| GHGuardant Health Inc | $10.1M | 6.2% | −18.4% |
| PRAXPraxis Precision Medicines I | $9.1M | 5.6% | −40.2% |
| TGTXTg Therapeutics Inc | $9.1M | 5.6% | New |
| COGTCogent Biosciences Inc | $8.1M | 5.0% | −24.4% |
| IONSIonis Pharmaceuticals Inc | $7.0M | 4.3% | −19.9% |
| LLYEli Lilly & Co | $6.6M | 4.1% | −21.7% |
| ABVXAbivax Sa | $6.2M | 3.9% | New |
| ALMSAlumis Inc | $5.8M | 3.5% | −26.8% |
| CYTKCytokinetics Inc | $5.1M | 3.2% | −42.1% |
| ELVNEnliven Therapeutics Inc | $5.1M | 3.1% | −54.5% |
| VERAVera Therapeutics Inc | $4.2M | 2.6% | −15.4% |
| UNHUnitedhealth Group Inc | $4.0M | 2.5% | −25.3% |
| TXG10x Genomics Inc | $3.9M | 2.4% | −33.4% |
| NTRANatera Inc | $3.7M | 2.3% | −26.0% |
| Uniqure NvCUSIP N90064101 | $3.7M | 2.3% | New |
| RYTMRhythm Pharmaceuticals Inc | $3.6M | 2.2% | −20.6% |
| MAZEMaze Therapeutics Inc | $3.4M | 2.1% | +29.6% |
| GLUEMonte Rosa Therapeutics Inc | $3.3M | 2.0% | −23.6% |
| MLTXMoonlake Immunotherapeutics | $3.2M | 2.0% | −22.7% |
| Alkermes PLCCUSIP G01767105 | $3.2M | 2.0% | −27.1% |
| LQDALiquidia Corporation | $3.1M | 1.9% | −14.4% |
| UTHRUnited Therapeutics Corp Del | $2.9M | 1.8% | −23.3% |
| GKOSGlaukos Corp | $2.8M | 1.7% | −4.8% |
| ARWRArrowhead Pharmaceuticals In | $2.6M | 1.6% | −29.5% |
| AGIOAgios Pharmaceuticals Inc | $2.6M | 1.6% | −43.6% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| GHGuardant Health Inc | March 31, 2024 | +627.2% | $10.1M |
| ALMSAlumis Inc | September 30, 2025 | +605.3% | $5.8M |
| COGTCogent Biosciences Inc | March 31, 2025 | +546.1% | $8.1M |
| LQDALiquidia Corporation | June 30, 2025 | +539.9% | $3.1M |
| NTRANatera Inc | December 31, 2023 | +333.3% | $3.7M |
| TXG10x Genomics Inc | June 30, 2025 | +231.1% | $3.9M |
| ELVNEnliven Therapeutics Inc | December 31, 2025 | +229.5% | $5.1M |
| ARWRArrowhead Pharmaceuticals In | September 30, 2025 | +136.3% | $2.6M |
| IONSIonis Pharmaceuticals Inc | December 31, 2024 | +126.8% | $7.0M |
| ADAGAdagene Inc | December 31, 2025 | +122.2% | $2.1M |
Sold off last quarter
- ELVElevance Health Inc Formerly was $4.3M
- Apellis Pharmaceuticals IncCUSIP 03753U106 was $3.4M
- AVTXAvalo Therapeutics Inc was $2.4M
- Soleno Therapeutics IncCUSIP 834203309 was $2.1M
- FDMT4d Molecular Therapeutics In was $1.2M
- NXTCNextcure Inc was $1.2M
- PALIPalisade Bio Inc was $1.1M
- LPCNLipocine Inc New was $486K
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +17.5% | +14.8% |
| March 31, 2026 | +1.2% | −4.6% |
| December 31, 2025 | +32.2% | +2.4% |
| September 30, 2025 | +26.8% | +7.8% |
| June 30, 2025 | +8.5% | +10.5% |
| March 31, 2025 | −9.3% | −4.6% |
| December 31, 2024 | −4.9% | +2.1% |
| September 30, 2024 | +4.4% | +5.4% |
| June 30, 2024 | +0.7% | +4.0% |
| March 31, 2024 | +9.9% | +10.0% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Exome Asset Management LLC Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2011932&type=13F-HR&dateb=&owner=include&count=40CIK 2011932
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/2011932/000142050626001714/Filed August 14, 2026 · accession 0001420506-26-001714